Features | Partner Sites | Information | LinkXpress
Sign In
Schiller
TeraRecon
VIEWORKS

Simplified Alzheimer’s Disease Diagnosis Using PET Imaging and More Effective Criteria

By Medimaging International staff writers
Posted on 24 Jul 2014
According to French investigators, over one-third of patients receive an incorrect diagnosis of Alzheimer’s disease (AD). To reduce the number of errors, the diagnostic criteria available must be the most reliable possible, especially at the very early stages of the disease. For the past 10 years, an international team of neurologists has been working towards this objective. The researchers recently introduced new diagnostic criteria, in particular, biomarkers. These are authentic signatures of the disease, and are present from the first symptoms (prodromal stage).

In the June 2014 issue of the Lancet Neurology journal, Dr. Bruno Dubois, from the National de la Santé et de la Recherche Médicale (Inserm; Paris, France) and Pierre and Marie Curie University (Paris, France) /AP-HP Joint Research Unit 975) and colleagues have developed a simplified diagnosis based on the most specific criteria of the disease, which should have a major impact in clinical practice.

AD is the most common (70%) form of dementia. The real challenge of a definitive diagnosis is to know how to differentiate this disease from other types of dementia, and establish the diagnosis as effectively and as early as possible.

In 2005, an international group of neurologists, coordinated by Inserm’s Dr. Bruno Dubois, came together to redefine the diagnostic criteria established in 1984. Up to then, it had been necessary to await the death of a patient in order to establish a diagnosis of AD with certainty by examining the lesions in his/her brain. And in the living, only a probability of disease could be inferred, and only at a late stage, based on a certain threshold of severity of dementia.

In 2007, the international team broke these hypotheses apart. The researchers introduced new diagnostic criteria, particularly biomarkers. These are authentic signatures of the disease, and are present from the initial symptoms (prodromal stage). The publication of these findings initiated a transformation. Researchers then observed that with these new criteria, “36% of their patients included in a therapeutic trial based on previous clinical criteria did not have Alzheimer’s disease,” reported Prof. Dubois. However, although this analysis involved only a subgroup of patients, the implications are serious. Patients did not receive the correct treatment and/or care. Moreover, flawed patient selection might have had an impact on the lack of efficacy observed for the new treatment.

Since 2007, many studies have been published. The international group decided to analyze this literature to make the diagnostic algorithm for AD simpler and more reliable. “We have reached the end of the road; we have arrived at the essence, something refined, resulting from an international consensus,” indicated Prof. Dubois. The diagnosis of Alzheimer’s disease will henceforth rely on “just a couple of clinical-biological criteria for all stages of the disease.”

Most of the time, the diagnosis of AD is based primarily on a suggestive clinical picture. It is subsequently confirmed or rejected using a biomarker. As regards the clinical picture, there are three scenarios: (1) typical cases (80%–85% of all cases): impairment of episodic long-term memory (known as amnestic syndrome of the hippocampal type and corresponding to difficulty remembering a list a words, even with clues, for example); (2) atypical cases (15%–20% of cases): atrophy of the posterior part of the cerebral cortex or logopenic aphasia (impairment of verbal memory where the patient inverts the syllables of a word when repeating it, for example), or frontal brain damage, which results in behavioral problems; (3) preclinical states: asymptomatic at-risk (patients without symptoms, but who are fortuitously discovered to have positive biomarkers during scientific studies), and presymptomatic (with a genetic mutation).

One of the following two biomarkers is required: (1) in the cerebrospinal fluid (obtained by lumbar puncture) to ascertain abnormal levels of brain proteins (reduced beta amyloid protein and increased tau protein); (2) and in the brain by positron emission tomography (PET) neuroimaging to determine the elevated retention of amyloid tracer.

This simpler and more effective algorithm is important, mainly for research (therapeutic trials, characterization of the disease, monitoring of patient cohorts), according to the investigators. Outside of research, the use of biomarkers, which is expensive and/or invasive, currently remains limited to young patients or difficult or complex cases in specialty centers.

Related Links:
National de la Santé et de la Recherche Médicale
Pierre and Marie Curie University




Channels

Radiography

view channel

Coronary CT Used to Measure a Recreational Athlete's Risk of a Cardiovascular Event

Researchers presented the results of the Measuring Athlete's Risk of Cardiovascular events (MARC) study at the 2015 European Congress of Radiology (ECR) in Vienna (Austria).  Researchers at the University Medical Center Utrecht (UMC; Utrecht, Netherlands) investigated the added value of low-dose ECG-triggered Coronary... Read more

MRI

view channel

Bayer Shows its Latest Development in MR Injectors

The latest contrast delivery and management innovation from Bayer HealthCare takes the form of the Medrad MRXperion magnetic resonance Injection System, launched at the European Congress of Radiology 2015 in Vienna (Austria). Bayer (Leverkusen, Germany) has begun to introduce the product in select countries with commercial... Read more

Ultrasound

view channel

Breakthrough Ultrasound Treatment for Alzheimer's Developed

A new, revolutionary technique that can be used to treat Alzheimer's disease and restore memory has been discovered by researchers at the University of Queensland (Queensland, Australia). The treatment uses noninvasive ultrasound to break apart neurotoxic amyloid plaques that cause cognitive decline and memory loss,... Read more

General/Advanced Imaging

view channel
Image: Measuring the Magnetic Activity in the Brain of a Child, Using a MEG machine. (Photo courtesy of Children\'s Hospital of Philadelphia).

Study Suggests Language Delay Linked to Chromosome Deletion in Children with Neurological Disorders

A study found that children with neuro-developmental problems born with DNA duplications or deletions on part of chromosome 16, show measurable delays in their ability to process sound and language.... Read more

Imaging IT

view channel

New Release of Image Management and Advanced Visualization Solution Unveiled at ECR 2015

A new version of an enterprise medical image management and advanced visualization solution has been launched at the 2015 European Congress of Radiology (ECR) in Vienna (Austria). The visualization solution provider also released new processing capabilities for cardiac Magnetic Resonance (MR), optimized low-dose workflow... Read more

Industry News

view channel

Analysis of Worldwide CT Scanner Sector Released

A report by Kalorama Information (New York, NY, USA) analyzing the global Computed Tomography (CT) market has been published. The report surveyed the CT market outlook until 2018, and the drivers behind the changes. The report investigated CT market sizing, market forecast to 2018, analysis of trends, how the market... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.